A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome

Abstract

Liver disease complicates human immunodeficiency virus (HIV)/acquired immune deficiency syndrome; however, liver pathology data are limited, particularly from high HIV prevalence countries. We investigated the spectrum and clinicopathological correlates of liver pathology in a high HIV burden setting. In a single-center study, all HIV/acquired immune deficiency syndrome patients with complete clinical and demographic data who underwent liver biopsy were analyzed and clinicopathologically assessed by hepatologists and one of two experienced liver pathologists. We evaluated 301 patients, with a median age of 34 (interquartile range 29-40) years. Women (n 5 143) were younger than men (n 5 158), with a median age of 33 (interquartile range 28-37) versus 35 (interquartile range 31-41) years, P 5 0.001. The majority, 76.1%, were black African. Median CD4 at time of biopsy was 127 (52-260) cells/mm 3 . Drug-induced liver injury was the predominant finding (42.2%), followed by granulomatous inflammation (29%), steatosis/ steatohepatitis (19.3%), hepatitis B (19%), and hepatitis C coinfection (3.3%), with more than one pathology in 16.2%. With granulomatous inflammation, 52% met the criteria for tuberculosis immune reconstitution syndrome. By univariate analysis, cotrimoxazole and antiretroviral therapy conferred risk for drug injury (odds ratio [OR] 5 2.78 [1.72-4.48], P < 0.001; OR 5 1.69 [1.06-2.68], P 5 0.027). In multivariate analysis, cotrimoxazole was associated with a cholestatic or ductopenic injury (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19).89], P < 0.001; OR 5 17.6 [3.26-95.3], P < 0.0001); efavirenz was associated with nonspecific hepatitis or submassive necrosis (OR 5 4.3 [1.92-9.83], P < 0.001; OR 5 10.46 [2.7-40.5], P < 0.001). Cholestatic injury was associated with female gender and a CD4 of >200 cells/mm 3 , and submassive necrosis was associated with younger age. Hepatitis B demonstrated no association. Conclusion: In a high HIV burden area, drug-induced liver injury due to antiretroviral therapy and cotrimoxazole was a frequent clinicopathological finding; Mycobacterium tuberculosis was the leading opportunistic infection, with more than half of patients fulfilling criteria for tuberculosis immune reconstitution syndrome; liver biopsy remains a useful diagnostic procedure in this setting. (HEPATOLOGY 2015;61:1721-1729

Alcohol use, viral hepatitis and liver fibrosis among HIV‐positive persons in West Africa: a cross‐sectional study

“…This finding suggests that through its suppressive effect on HIV replication, ART has the potential to prevent and/or reduce liver fibrosis in HIV-positive patients. Conversely, exposure to ART drug regimens with a known hepatic toxicity could also promote liver fibrosis [33,34]. The cross-sectional nature of our study design prevents any causal relation between ART use and the occurrence of liver fibrosis.…”

Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

“…Contrary, NNRTIs are known for their potential to cause elevated liver enzymes, but have so far not been linked to fibrosis progression and remain commonly utilized (112). In addition, a recent study of liver biopsies in HIV-infected patients demonstrated drug induced liver injury due to antiretroviral therapy in a significant number of patients (113).…”

Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets

“…21 Series HIV-HBV co-infection promotes an aggressive disease course of hepatitis B by the following mechanisms: increasing replication of the virus and rates of HBV reactivation; increasing risk of acute liver failure, chronicity of newly acquired HBV infections, and occult infection (characterised by absence of HBsAg and low viral replication; HBV DNA concentration <200 IU/mL); accelerating progression to fibrosis and cirrhosis, with hepatocellular carcinoma occurring at a younger age; and increasing the risk of ART hepatotoxicity. 14,15,17,18,[22][23][24][25][26][27][28][29] Liver-related mortality is twice as high for individuals who are co-infected with HIV-HBV as it is for those who are co-infected with HIV-HCV. Individuals with a CD4 cell count of less than 200 cells per mL have a risk of liver-related deaths that is 16•2 times higher than that of those with a CD4 count of more than 350 cells per mL.…”